Schering-Plough says clinical data demonstrate efficacy of Levitra; plus more stocks in the news Friday
Qualcomm (QCOM) Posts $0.36 vs. $0.32 fourth quarter earnings per share (EPS) (GAAP) on a 28% revenue rise. Sees $0.35-$0.37 first quarter GAAP EPS on $1.98 billion to $2.08 billion revenue, and $1.45-$1.50 fiscal year 2007 GAAP EPS on $8.1 billion to $8.6 billion revenue.
Whole Foods Market (WFMI) Posts $0.28 vs. $0.06 fourth quarter EPS on 8.6% higher same-store sales and 15% higher total sales. Posts 6.8% higher Oct. same-store sales. Sees fiscal year 2007 total sales growth of 13%-17% and comp growth of 6%-8%.
Red Robin Gourmet (RRGB) Posts $0.36 vs. $0.39 third quarter EPS as stock option expense and other items offset an 0.8% same-restaurant sales rise and 30% total revenue rise.
Electronic Arts (ERTS) Posts $0.21 vs. $0.15 second quarter EPS (non-GAAP) on a 16% revenue rise. Sees $0.50-$0.60 third quarter non-GAAP EPS on $1.2 billion to $1.3 billion revenue. Ups fiscal year 2007 EPS view to $0.55-$0.70 from $0.35-$0.65.
Cephalon (CEPH) Posts $1.61 third quarter EPS (adjusted) on a 56% revenue rise. Raises 2006 total adjusted sales forecast to $1.66 billion to 1.675 billion, and basic adjusted EPS to between $5.10 and $5.20. Sets $1.675 billion to $1.725 billion 2007 sales guidance and $4.50-$4.60 basic adjusted EPS.
Schering-Plough (SGP) Says clinical data demonstrated continued efficacy and tolerability of Levitra in men with erectile dysfunction, high blood pressure, diabetes and/or dyslipidemia.
JDS Uniphase (JDSUD) Posts $0.08 first quarter loss vs. $0.34 loss (GAAP) on a 23% revenue rise.